Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  LJUBLJANA STOCK EXCHANGE, INC.  >  Krka d.d. Novo Mesto    KRKG   SI0031102120

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2017 1 252 M
EBIT 2017 184 M
Net income 2017 147 M
Finance 2017 4,80 M
Yield 2017 4,96%
Sales 2018 1 297 M
EBIT 2018 195 M
Net income 2018 174 M
Finance 2018 19,9 M
Yield 2018 5,22%
P/E ratio 2017 12,58
P/E ratio 2018 10,66
EV / Sales2017 1,48x
EV / Sales2018 1,41x
Capitalization 1 852 M
More Financials
Company
KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products.It offers prescription pharmaceuticals and non-prescription products.It operates through the following geographical segments: European Union, South-East... 
Sector
Pharmaceuticals
Calendar
11/16Earnings Release
More about the company
Surperformance© ratings of Krka d.d. Novo Mesto
Trading Rating : Investor Rating :
More Ratings
Latest news on KRKA D.D. NOVO MESTO
07/18 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2016 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2015 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2015 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2014 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2013 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
2012DJEU Sends Objections on Drug to Servier, Other Manufacturers
2012 KRKA D.D. NOVO MESTO : ex-dividend day for annual dividend
More news
Sector news : Generic Pharmaceuticals
11:31aDJEuropean Corporate Roundup for Thursday
08:48aDJMERCK AND : Chenault Among Few Black CEOs -- WSJ
07:53aDJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 58,3 €
Spread / Average Target 3,3%
EPS Revisions
Managers
NameTitle
Jože Colaric President-Management Board & CEO
Jože Mermal Chairman-Supervisory Board
Brane Kastelec Director-Finance
Aleš Rotar Director-Research & Development
Miran Kapš Director-Information Technology